Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.

Abstract: The invention provides a pharmaceutical composition comprising as an active ingredient a combination of three isolated monoclonal antibodies or any antigen-binding fragment thereof which bind ricin toxin and neutralize its toxic effects, and a pharmaceutically acceptable carrier, excipient or diluent. The invention also provides a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition.

Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.

Abstract: Embodiments concern compositions and methods involving recombinant antibodies to histone post-translational modifications. The invention provides compositions and methods for histone methyltransferase assays. In certain embodiments, the compositions and methods involve a recombinant antibody that binds histone H3 fragment harboring biomarkers such as H3K9me3 mark, H3K4me3 mark, H3K36me3 mark, H3K27me3, H3K9me3 and H3S10phos or a recombinant antibody that binds histone H4 fragment harboring H4K20me3 mark.

Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease.

Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Abstract: The invention provides dual specific anti-FGFR2 and FGFR3 (FGFR2/3) antibodies, and compositions comprising and methods of using these antibodies.

Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Abstract: Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.

Abstract: This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

Abstract: The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.

Abstract: This disclosure provides anti-MUC1 binding agents (e.g., antibodies and chimeric antigen receptors) and methods of treatment, prophylaxis, detection, and diagnosis using the same.

Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.

Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Abstract: The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX2X3X4A X6X7EIW X11LPNL X16X17X18QX20 X21AFIX25 X26LX28D, and ii) an amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.

Abstract: An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59 YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3) For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID No. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.

Abstract: Improved methods of treatment are provided for patients suffering from cancer. The methods identify whether a tumor will be responsive to treatment with a therapeutic regime that includes anti-Her2 therapeutic agents. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.

Abstract: The present invention intended to provide an artificial polyclonal immunoglobulin composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other.

Abstract: A method of modifying a polymer having hydroxyl groups, selected from the group of polysaccharides and lignin, to give a modified polymer comprising the step of contacting said polymer with at least one organic phosphonate salt in order to chemically modify the polymer, said organic phosphonate salt being in a liquid phase. The method of polymer modification provides novel polymers. Modified polymers obtained from a polymer having been treated with at least one organic phosphonate salt are also disclosed. The modified polymers can be used as such or separated and optionally recovered from the solution, optionally being formed into particular materials or shapes.

Abstract: The present invention relates to site-selective modification of polysaccharides at their reducing end by conjugation with a single aminoxy-Regioselective Addressable Functionalized Template (RAFT) peptide.

Abstract: The invention relates to aqueous, cationically stabilized primary dispersions comprising dispersed polymer particles having a Z-average particle diameter of 5 to 500 nm and which are obtainable by emulsion polymerization of at least one olefinically unsaturated monomer (A). The emulsion polymerization takes place in the presence of one or more emulsifiers (E) having the following general formula: R1—N(R2)(R3), where R1 is a moiety with 15 to 40 carbon atoms which contains at least one aromatic group and at least one aliphatic group, and which contains at least one functional group selected from hydroxyl groups, thiol groups, and primary or secondary amino groups, and/or has at least one carbon-carbon multiple bond, and R2 and R3, independently of one another, are the same or different aliphatic moieties containing 1 to 14 carbon atoms.

Abstract: A catalyst component comprising Ti, Mg, Cl, and an electron donor compound having porosity of at least 0.2 cm3/g and characterized by the fact that it further comprises Cu oxide, with the proviso that when the electron donor compound is selected from esters of phthalic acids, the porosity is of at least 0.45 cm3/g.

Abstract: The invention relates to a process for the isolation of (per)fluorinated polymers containing sulfonyl fluoride functional groups from a polymerization latex. The process comprises adding the polymerization latex to an aqueous electrolyte solution under high shear stirring at a temperature equal to or lower than the glass transition temperature of the polymer. The invention further relates to the (per)fluorinated polymers containing sulfonyl fluoride functional groups isolated by the process and characterised by a loss of weight at 200° C. lower than 1% as determined by thermogravimetric analysis.

Abstract: A first tire member manufacturing method includes an operation in which a pre-coagulation rubber latex containing carbon black, for which a ratio of specific surface area as determined by nitrogen adsorption N2SA (in units of m2/g) to an amount of iodine absorption IA (in units of mg/g) is not less than 1.00, is coagulated to obtain a coagulum; an operation in which a compound according to Formula (I), below, is added to the water-containing coagulum; and an operation in which the compound according to Formula (I), below, is dispersed within the coagulum. In Formula (I), R1 and R2 each indicates a hydrogen atom, an alkyl group having 1 to 20 carbons, an alkenyl group having 1 to 20 carbons, or an alkynyl group having 1 to 20 carbons, R1 and R2 may be the same or different, and M+ indicates sodium ion, potassium ion, or lithium ion.

Abstract: An organosiloxane graft polyvinyl alcohol polymer contains a structural unit shown by the following general formula (1), wherein M1 and M2 represent a hydrogen atom, an acetyl group, or a siloxane group shown by the following general formula (2), provided that at least one of M1 and M2 is a siloxane group shown by the general formula (2); and A represents a single bond or a linking group, wherein R1 represents a monovalent organic group having 1 to 6 carbon atoms; R2, R3, and R4 each represent a monovalent organic group having 1 to 6 carbon atoms or a siloxy group shown by —OSiR5R6R7, where R5, R6, and R7 each represent a monovalent organic group having 1 to 6 carbon atoms; “n” represents an integer of 1 to 10; and “a” represents an integer of 0 to 2.

Abstract: Catalyst systems and methods for making and using the same. A method for making a catalyst support includes forming a mixture of a support material and a fluoride donor. The mixture is added to a fluidized bed reactor. The mixture is fluidized to form a fluidized bed while maintaining a ratio of a pressure drop across a distributor plate to a pressure drop across the fluidized bed of greater than about 7%. The mixture is calcined to decompose the fluoride donor, forming a fluorinated support.

Abstract: Quinolinyldiamido transition metal complexes are disclosed for use in alkene polymerization to produce multimodal polyolefins.

Abstract: A polymer comprising

Abstract: Some embodiments described herein relate to new polymer coatings for surface functionalization and new processes for grafting pre-grafted DNA-copolymers to surface(s) of substrates for use in DNA sequencing and other diagnostic applications.

Abstract: Disclosed are polyethylene polymers with good melt strength that can provide enhanced properties for compositions including such polyethylene polymers and films made therefrom.

Abstract: A process for the preparation of polyolefins by polymerizing olefins at temperatures of from 20 to 200° C. and pressures of from 0.1 to 20 MPa in the presence of a polymerization catalyst and an antistatically acting composition in a polymerization reactor, wherein the antistatically acting composition is a mixture comprising an oil-soluble surfactant and water and the use of an antistatically acting composition comprising an oil-soluble surfactant and water as antistatic agent for the polymerization of olefins at temperatures of from 20 to 200° C. and pressures of from 0.1 to 20 MPa in the presence of a polymerization catalyst.

Abstract: The present invention provides a catalyst component for olefin polymerization, obtained by a reaction of magnesium, titanium, halogen and an internal electron donor, the internal electron donor comprising an imine compound as shown in Formula Z. The present invention also provides a preparation method of the catalyst component, and a catalyst for olefin polymerization containing the same. When the catalyst of the present invention is used for olefin polymerization reaction, the catalyst has a high activity, and a slow rate of activity decay, and the obtained polymer has a high isotacticity index, and a wide molecular weight distribution.

Abstract: Provided is a solid catalyst component for olefin polymerization, which comprises Mg, Ti, a halogen and an electron donor. The electron donor is selected from at least one of ring-substituted ether-acid ester compounds of the general formula (I). Also provided are a catalyst containing the solid catalyst component and the application of the catalyst in reactions of olefin polymerization, particularly in the reaction of propylene polymerization.

Abstract: This invention pertains to fluoroallylsulfonyl azide compounds of formula: CF2?CF—CF2—Rf—SO2N3 formula (I) wherein Rf is a divalent (per)fluorinated group, optionally comprising one or more than one ethereal oxygen atom [monomer (Az)], which are useful as functional monomers in fluoropolymers, to the fluoropolymers which comprise recurring units derived from such fluoroallylsulfonyl azide compounds, to a process for their manufacture, to a curable compound comprising the same and to a method for crosslinking the same.

Abstract: The present invention relates to a copolymer obtainable by copolymerization of at least three ethylenically unsaturated monomers each different from one another, the copolymer having at least three structural units (S1) and (S2) and (S3) different from one another, to the use of this copolymer as an adhesion-promoting additive in an aqueous coating composition, to an aqueous coating composition comprising at least one polymeric resin (A1), at least one pigment (B), and at least one copolymer of the invention, used as adhesion-promoting additive, as component (C), and also to methods for at least partly coating a substrate with a basecoat and for at least partly coating a substrate with a multicoat paint system.

Abstract: A process for preparing water-absorbing polymer beads with high permeability by polymerizing droplets of a monomer solution, comprising monomers bearing acid groups, in a gas phase surrounding the droplets, wherein the monomer solution comprises polyvalent cations and the polymer beads have a mean diameter of at least 150 ?m.

Abstract: The present invention relates to a method for preparing a diene-based rubber latex having improved impact strength, gloss and flexibility, diene-based rubber latex prepared therefrom, and an acrylonitrile-butadiene-styrene graft copolymer having improved impact strength and production yield while having reduced rubber solid content ratio by comprising the same.

Abstract: A method for efficiently producing a poly(ethylene glycol)-b-poly(halomethylstyrene), a novel poly(ethylene glycol)-b-poly(halomethylstyrene) produced using the method, and a derivative thereof. The target novel copolymer can be provided by introducing a functional group, which enables reversible addition-fragmentation chain transfer (RAFT) polymerization, to the ? terminal of poly(ethylene glycol) and copolymerizing the resulting poly(ethylene glycol) with a halomethylstyrene.

Abstract: There is provided an adhesive composition comprising (a) a polyisocyanate component comprising (i) monomeric 4,4? methylene diphenyl diisocyanate and (ii) an isocyanate functional prepolymer that is the reaction product of a prepolymer reactant mixture comprising (A) monomeric 4,4? methylene diphenyl diisocyanate, and (B) one or more diol having OH equivalent weight of 225 or less, and (C) one or more triol having OH equivalent weight of 1400 or more, and (b) a polyol component comprising one or more polyol.

Abstract: A two component composition for making chemical mechanical polishing pad for polishing a semiconductor substrate is provided comprising a liquid aromatic isocyanate component having an unreacted isocyanate (NCO) concentration of from 15 to 40 wt. %, based on the total solids weight of the aromatic isocyanate component, such as methylene di(phenylisocyanate) (MDI), a liquid polyol component of a polyol having a polyether backbone and having from 5 to 7 hydroxyl groups per molecule, and a curative of one or more polyamine or diamine, wherein the reaction mixture comprises 50 to 65 wt. % of hard segment materials, based on the total weight of the reaction mixture. The composition when mixed cured to form a polyurethane reaction product. Also provided are CMP polishing pads made from the polyurethane reaction product by spraying the composition into a mold.

Abstract: The invention relates to a compound prepared by (i) reacting (a) at least one compound selected from diisocyanate, polyisocyanate, or mixture thereof; (b) at least one isocyanate-reactive compound selected from a fluorinated alcohol; a cyclic or acyclic sugar alcohol which is substituted with at least one —R1, —C(O)R1, —(CH2CH2O)n(CH(CH3)CH2O)mR2, —(CH2CH2O)n(CH(CH3)CH2O)mC(O)R1, or mixtures thereof; or mixtures of a fluorinated alcohol and a substituted cyclic or acyclic sugar alcohol; and (c) at least one isocyanate-reactive ethylenically unsaturated compound; wherein each n is independently 0 to 20; each m is independently 0 to 20; m+n is greater than 0; each R1 is independently a linear or branched alkyl group having 5 to 29 carbons optionally comprising at least 1 unsaturated bond; each R2 is independently —H, or a linear or branched alkyl group having 6 to 30 carbons optionally comprising at least 1 unsaturated bond, or mixtures thereof; and (ii) reacting the reaction product of step (i) with a bisulfat

Abstract: Provided in the present invention are an epoxy resin composition, prepreg and laminate using the same, the epoxy resin composition comprising the following components: (A) an imide modified epoxy resin; and (B) a crosslinking agent, the imide modified epoxy resin being an epoxy resin having a structure of formula (1) and/or formula (2). The prepreg and laminate prepared from the epoxy resin composition have a high glass-transition temperature, a low dielectric constant, a low dielectric loss factor, a high heat and humidity resistance, a high toughness and a good processability.

Abstract: A vinyl ester resin composition comprising a reaction product of: (a) a polyepoxide resin; (b) an unsaturated carboxylic acid; and (c) a reactive carboxyl group terminated amphiphilic block copolymer, a reactive epoxy group terminated amphiphilic block copolymer, or a mixture thereof; and a cured thermoset composite product produced from the above vinyl ester resin composition.

Abstract: Described is a super elastic epoxy hydrogel that is easy to manufacture and can be engineered for various performance enhancements of the polymer. Also described are methods of enhancing the performance of this hydrogel and other hydrogels. Various polymer hydrogel composites, structures, and their uses are included, such as the actuator element comprising the hydrogel of the invention depicted in FIG. 2.

Abstract: Provided is a flexible wiring board having high durability. The present invention provides a flexible wiring board including a flexible substrate and a conductive film formed on the flexible substrate. The conductive film contains a conductive powder and a curd product of a heat curable resin. The conductive film has pencil hardness of at least 2H, based on a pencil scratch hardness test in accordance with JIS K5600 5-4 (1999). The conductive film has adhesiveness of at least 95/100 by a 100 squares cross-cut test in accordance with JIS K5400 (1990).